Status:
RECRUITING
Salvage MR-guided High-Dose-Rate Brachytherapy for Prostate Bed Recurrence After Radiotherapy in the PSMA PET Scan Era
Lead Sponsor:
University Health Network, Toronto
Conditions:
Prostate Cancer Recurrent
Prostate Cancer
Eligibility:
MALE
18+ years
Phase:
NA
Brief Summary
This is an interventional, single-centre, single-arm, non-randomized, prospective, feasibility trial investigating salvage MR-guided High-Dose-Rate brachytherapy for prostate bed recurrence after post...
Detailed Description
Patients who received previous adjuvant or salvage radiotherapy to the prostate bed \> Isolated prostate bed recurrence based on PSMA PET, biopsy-proven, and MR visible \> Baseline: QoLs questionnai...
Eligibility Criteria
Inclusion
- Patients who received previous RT to the prostate bed +/- pelvic nodal regions
- Prostate-bed recurrence identified by biopsy and/or MRI and/or PSMA-PET scan
- At least two continuous PSA elevations post RT and PSA above 0.2 ng/dl
- With or without ADT PSA doubling time from nadir greater than 6 months
- ECOG 0-2
- Age greater than 18 years
Exclusion
- Radiological (e.g. PSMA PET, CT, MRI or bone scan) evidence of or distant metastases
- History of ≥G3 gastrointestinal (GI) and genitourinary (GU) toxicities following RT
- Any contraindications to MR and/or brachytherapy
Key Trial Info
Start Date :
August 8 2024
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
March 1 2031
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT06508567
Start Date
August 8 2024
End Date
March 1 2031
Last Update
February 10 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Princess Margaret Cancer Centre
Toronto, Ontario, Canada, M5G1Z5